The coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has upended life as humankind knows it, leading to over 238,000,000 cases and 4,800,000 deaths worldwide at the time of writing. SARS-CoV-2 targets the angiotensin-converting enzyme 2 (ACE-2) receptors present in the nasal epithelium and lungs. Viral replication leads to a variety of clinical presentations and outcomes during the acute infectious process, including: asymptomatic disease; milder symptoms such as fever, dry cough, shortness of breath, abdominal pain, anosmia, and ageusia; and, in severe cases, hypoxemia, acute respiratory stress disease, and death. Complications are not limited to the respiratory tract and may present as multi-organ involvement varying from acute cardiac injury, coagulopathies, and multisystem inflammatory syndrome. Some survivors of the disease must also grapple with reduced health-related quality of life as a result of chronic lung fibrosis and central nervous system or mental health dysfunction, including post-traumatic stress disease, attention deficit, anxiety, and overall impaired cognitive function.
This learning activity has been designed to bring physicians knowledge of the strategies for the management of COVID-19 up to date and to improve their competence and performance in diagnosing and treating it.
HCPs including: Hospitalists and other primary care physicians, infectious disease physicians, pulmonologists, and critical care physicians; physician assistants, nurse practitioners, and pharmacists in those areas of specialty; and any other healthcare professionals with an interest in or who clinically encounter patients with acute COVID-19 infection.
This program is supported by educational grants from Gilead and Regeneron.
This activity is free of charge.
Release Date: January 30, 2022 -- Expiration Date: January 30, 2023
Faculty: Michael Niederman, M.D., MACP, FCCP, FCCM, FERS
Faculty introduction and disclosures
Acute Covid-19 infection introductory content
· Epidemiology and statistics
· Disease pathophysiology and associated hyperinflammatory state
· Clinical symptoms, presentation, complications
· Disease severity
· Predictors of outcomes, morbidity, and mortality
· Factors impacting therapeutic decisions, indication criteria
· Severity and risk stratification, severe/critical vs. non-severe disease
· Dyspnea and oxygen requirements
· Patient age and weight
· Presently available and investigational treatments, their roles in therapy, and literature support
· SARS-CoV-2 spike protein-targeting monoclonal antibodies, IgG1κ and IgG1λ; virus internalization inhibition
· Viral RNA-dependent RNA polymerase inhibition
· Janus kinase inhibition & IL-6 pathway inhibition
· Corticosteroid therapy
· Convalescent plasma
· ATI-450 MK2 pathway inhibition
· Granulocyte-macrophage colony-stimulating factor inhibition
· Identification of patients who may benefit from novel therapies, including EUA agents in hospitalized patients
· Hypoxemia, acute respiratory disease syndrome, and thromboembolic complication treatment and prevention
· Symptom and chronic anti-inflammatory medication management
· Monitoring and re-testing
· Other treatment challenges
· Special populations: pregnant or breastfeeding patients; influenza, HIV, or bacterial co-infection
· Overprescribing of antibiotics
· Treatment misinformation
· Patient case(s)
Summary, conclusions, and best practice recap
By the end of the session the participant will be able to:
ACCME Activity #201826245ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, CEO of ScientiaCME, has no relevant financial disclosures.
Commercial Support Disclosure: This program is supported by educational grants from Gilead and Regeneron.
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Vaccine hesitancy and denial: A problem for the ages coming into sharp focus during the pandemic
Overcoming barriers to the prevention and management of antimicrobial-resistant bacterial infections: updates from ID Week 2021
Cultural and Linguistic Competence
Frontiers in the treatment of systemic sclerosis interstitial lung disease: Therapeutic updates and best practices